Belsomra, Dayvigo, and Quviviq: A Clinical Comparison of the Orexin Antagonists
Why the newest sleep medication class works differently than everything that came before it — and which one I reach for most often.
For decades, insomnia treatment meant one thing: turning up the volume on GABA. Benzodiazepines, Ambien, Lunesta — all of them work by amplifying the brain's primary inhibitory neurotransmitter until the patient is sedated into sleep. It works, but it comes with tolerance, dependence, next-day cognitive fog, and in older patients, a real fall risk. The dual orexin receptor antagonists, or DORAs, take a completely different approach. Instead of sedating the brain, they block the signal that keeps it awake in the first place. In my practice, this class has become a first-line option for young adults with chronic sleep-onset or sleep-maintenance insomnia, especially those who are wary of dependence-prone medications or have already had a bad experience with one.
There are currently three FDA-approved DORAs on the market: suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq). They share a mechanism but behave quite differently in practice, and the differences matter a great deal when you're deciding which one to prescribe.
The Mechanism: Blocking the "Stay Awake" Signal
Orexin (also called hypocretin) is a neuropeptide produced by a small cluster of neurons in the hypothalamus. Its job is to promote and stabilize wakefulness by driving arousal centers in the brainstem that release dopamine, norepinephrine, histamine, and acetylcholine. Think of it as the brain's wakefulness switch: as long as orexin is binding to its two receptors, OX1R and OX2R, the arousal system stays lit up, even when the patient is exhausted and trying to fall asleep. This is the mechanism that keeps a wired, ruminating patient staring at the ceiling at 2 a.m.
All three DORAs block both orexin receptors, which lets the brain's natural sleep-promoting circuitry take over without a fight. This is why patients on a DORA often describe falling asleep differently than they did on a benzodiazepine or Z-drug — less like being knocked out, more like finally being allowed to drift off.
Research Snapshot
A network meta-analysis pooling data from thousands of insomnia patients found suvorexant at 20–40 mg and daridorexant at 10–50 mg were the most effective doses for helping people fall asleep faster and stay asleep longer, with lemborexant 5–10 mg also performing especially well for sleep onset. Separately, head-to-head comparisons have found daridorexant produces fewer side effects than suvorexant and better preserves next-day function.
Half-Life Is the Whole Story
If you remember nothing else from this article, remember this: with DORAs, half-life predicts everything about the side-effect profile. A longer half-life means more drug still circulating at 7 a.m., which means more grogginess getting the kids to school.
| Drug | Typical Dosing | Half-Life | Next-Day Residual Risk |
| Belsomra (suvorexant) | 10–20 mg | \~12 hours | Moderate |
| Dayvigo (lemborexant) | 5–10 mg | \~17–19 hours | Highest |
| Quviviq (daridorexant) | 25–50 mg | \~8 hours | Lowest |
Dayvigo's long half-life is exactly why it has the strongest sleep-maintenance effect of the three — it's still working at 5 a.m. when a shorter-acting drug has already tapered off — but that same property is what produces the "daytime hangover" some patients describe: a heavy, muffled-thinking feeling that can persist into the late morning, particularly at the 10 mg dose or in patients who are slow metabolizers. Belsomra sits in the middle. Quviviq, with roughly half the half-life of Dayvigo, is largely cleared by the time most patients need to be sharp, which is the main reason it's become my default starting DORA for working adults.
Why Quviviq Is My First Choice
I typically start patients on daridorexant 25 mg, titrating to 50 mg if sleep onset or maintenance is still a problem after one to two weeks. It is dosed once nightly, taken within 30 minutes of bedtime on an empty stomach or after a light meal — a fatty meal delays absorption and blunts the peak effect. Common side effects are headache, mild daytime sleepiness, and occasionally vivid dreaming, but at a rate meaningfully lower than what I see with Dayvigo. The short half-life also makes it my preferred option for patients with early call times, shift workers, or anyone who has to be cognitively sharp within eight hours of taking it. I still reach for Dayvigo in patients whose chief complaint is middle-of-the-night awakenings that Quviviq hasn't fully resolved, and Belsomra remains a reasonable second-line option, particularly for patients already familiar with it.
Case Vignettes
The following vignettes are composite patients, constructed from common presentations in my practice. They do not represent any single individual.
"Chris," 27, software engineer
Chris came in after two years of unsuccessful Ambien use — effective for a while, then increasingly unreliable, with mornings that felt "underwater." We switched him to Quviviq 50 mg. Three weeks in, he said: "I actually feel like a person at my 9 a.m. standup now. Falling asleep feels less like getting hit with a hammer and more like I just… stop fighting it." His only complaint was an occasional mild headache in the first week, which resolved on its own.
"Maria," 34, ICU nurse, rotating shifts
Maria's problem wasn't falling asleep, it was staying asleep through a 6-hour daytime sleep window after night shifts. We tried Quviviq first with partial benefit, then moved her to Dayvigo 5 mg. She reported: "I sleep so much deeper now, but on the days I have an afternoon shift right after, I feel groggy until I've been awake for like two hours. It's a trade I'm willing to make for the deep sleep, but it's noticeable." That daytime residual effect is a known trade-off of lemborexant's longer half-life, and we discussed timing her dose earlier in her sleep window to reduce it.
"David," 41, sales executive
David had tried both Belsomra and Dayvigo through a previous prescriber, on both of which he felt "hungover" for his early client calls. On Quviviq 25 mg he found the effect on sleep to be slightly less profound but far more tolerable functionally: "It doesn't knock me out the same way, but I'm also not walking into a 7 a.m. call feeling like I got hit by a truck. That trade is worth it for my job." This is a common theme — patients with high-stakes early mornings often prefer daridorexant's gentler but cleaner effect over a stronger but longer-acting alternative.
The Bottom Line
All three DORAs are safe, non-habit-forming (relative to Z-drugs and benzodiazepines), and represent a genuine mechanistic advance over older hypnotics. The choice between them mostly comes down to matching half-life to the patient's life: Quviviq for patients who need to be sharp early, Dayvigo for patients whose main problem is staying asleep and who can tolerate a slower morning, and Belsomra as a reasonable middle ground, especially for patients already stable on it. As always, the "best" DORA is the one that gets a specific patient asleep without stealing their next morning.
Struggling With Sleep?
Dr. Mark Agresti offers integrative, evidence-based psychiatric care for insomnia and other sleep disorders, combining medication management with lifestyle and nutritional strategies. In-person appointments are available at our Palm Beach office, with telemedicine offered statewide throughout Florida.
44 Cocoanut Row, Suite M202, Palm Beach, FL 33480
(561) 760-4107 | [email protected] | DrMarkAgresti.com
Keywords: orexin receptor antagonists, DORA, Quviviq, daridorexant, Dayvigo, lemborexant, Belsomra, suvorexant, insomnia treatment, sleep medication comparison, Palm Beach psychiatrist, young adult insomnia
Hashtags: #Insomnia #SleepMedicine #Quviviq #Dayvigo #Belsomra #Psychiatry #PalmBeach #SleepHealth #MentalHealth